Written by: Israel Investor Newsletter | July 20, 2008
Israel Stocks Trading in the U.S.
UPDATED 7/2008
Top 30 Israeli Stocks in the U.S. by Market Cap
Teva Pharmaceutical Industries Ltd (TEVA)
Marvell Technology Group Ltd. (MRVL)
Amdocs Limited (DOX)
Check Point Software Technologies Ltd. (CHKP)
Partner Communications Company Ltd (PTNR)
Perrigo Company (PRGO)
NDS Group plc (NNDS)
Cellcom Israel Ltd. (CEL)
Africa Israel Invts Ltd (AFIVY.PK)
Comverse Technology Inc. (CMVT.PK)
Elbit Systems Ltd. (ESLT)
Ormat Technologies, Inc. (ORA)
Nice Systems Ltd. (NICE)
Equity One, Inc. (EQY)
Savient Pharmaceuticals, Inc. (SVNT)
Verifone (PAY)
Elbit Medical Imaging Ltd (EMITF)
Electronics for Imaging, Inc. (EFII)
Verint Systems Inc. (VRNT.PK)
Zoran Corporation (ZRAN)
Blue Square Israel Ltd. (BSI)
Mellanox Technologies, Ltd (MLNX)
Given Imaging Ltd. (GIVN)
Gilat Satellite Networks Ltd (GILT)
Alon USA Energy, Inc. (ALJ)
Alvarion Ltd. (ALVR)
Delek US Holdings, Inc. (DK)
Ness Technologies, Inc (NSTC)
Syneron Medical Ltd. (ELOS)
For a full list of all Israeli firms traded in the U.S., click here.
Written by: Aaron Katsman | January 10, 2008
Aaron Katsman
www.IsraelNewsletter.com
I would be remiss if I neglect to mention that tonight is my wife’s birthday. This post is serving me as a reminder that I still need to buy her a gift. Maybe I will get her a subscription the the IOI Premium Newsletter! With gold prices surging, I can’t afford to by her actual jewelry, but I can afford to buy some shares in these 2 little-known Israeli stocks, and they are sure to be DIAMONDS in the rough.
Elbit Medical Imaging(EMITF) stock has dropped nearly 20% in the last few weeks. The real estate and bio-tech company was a big winner for investors in ‘07 and even with a slow start to ‘08, I look at ElbitMedical as a star performer this year as well. They are opening a mall in Poland( maybe I can get some cheap jewelry there) which is a continuation of their plans to continue building out the real estate holdings in Eastern European along with some new projects in India. As I have mentioned before, the real story with Elbit Medical is their very large stake in two of the most exciting private (though an IPO is definitely in the cards) companies Israel has to offer. Insightec ltd., develops a product that combines MRI technology with focused ultrasound in order to treat serious diseases such as bone, liver and brain tumors, without the invasive procedures that are currently used. The other private company is Gamida Cell. Gamida Cell is developing, along with the aforementioned Teva, a line of cell therapy products for the treatment of such diseases as leukemia and lymphoma.
Jacada(JCDA) a leading provider of unified desktop and process optimization solutions for customer service operations, has been signing deals right and left and a few weeks ago announced that they were selling their Application Modernization Business to Software AGfor $26 million. They are doing this to solely focus on high growth business, to position Jacada as a pureplay in the call center solutions business. The firm provides a single, unified workspace for customer service organizations managing lots of legacy and disparate software systems. My buddy Zack”I love the Internet” Miller had a great analysisof this deal. I really think Jacada is poised to fly, and in fact with all the current selling on Wall Street, Jacada stock has actually been inching up.
Happy birthday!
Disclosure: Author’s fund holds a position in EMITF and JCDA. He has no position in any other stock mentioned as of 1/9/08.
Please see our Disclaimer HERE.
NEW! Introducing Israel Opportunity Investor, our monthly subscription-only newsletter. Stay ahead of the game and make smart decisions in Israel stocks. Go here to learn more.
Aaron Katsman is Managing Editor of the Israel Opportunity Investor newsletter. He is lead portfolio manager for the Israel Growth Portfolio and Managing Director of America Israel Investment Associates, LLC. For more information, go to www.israelnewsletter.com or call 1-888-327-6179, or email aaron@profile-financial.com.
Leave a comment
Category:
Jacada,
emitf,
internet,
israel
Tags:
biotech,
eastern-europe,
elbit,
emitf,
India,
israel stocks in US,
Jacada,
jcda,
real estate,
technology,
Teva
Written by: Zack Miller | November 15, 2007
I stumbled across the Reuters Health Summit that’s taking place in New York this week. Interestingly enough, they’re blogging the conference, so cheap investors like me can “attend” remotely. You can find the blog for the summit here.
Israeli generics giant, Teva Pharmaceuticals (Nasdaq: TEVA), participated and there’s a great (short) audio clip on what Teva believes in happening in the biogenerics space during and after the election cycle. Go here to check it out.
Written by: Aaron Katsman | September 19, 2007
By Aaron Katsman
www.IsraelNewsletter.com
Emerging market guru Mark Mobius, continues to gain momentum in his bid to block the sale of Taro Pharmaceuticals(TAROF.pk) to the Indian drug company Sun Pharmaceutical Industries Ltd. Taro delayed it’s planned shareholder meeting after it became apparent that they couldn’t assure the votes needed to win merger approval. While delay tactics may have worked in the past, new judge Michal Agmon-Gonen, won’t put up with it any longer. She’d fed up and she’s not gonna take it anymore.
Judge Agmon-Gonen schedule a hearing for January 13, 2008. In the event that Taro again postpones its shareholders meeting, the judge said, “If no shareholders meeting is held, the hearing on this date will decide on how Templeton’s(BEN) petition will be heard, without waiting for the results of the shareholders meeting.”
Taro has used every trick under the sun to stall. Taro notified the SEC that the audit of its 2006 financial report by Ernst & Young would be completed soon, and that financials for Q1 and Q2 of 2007 would be ready now. Once the financials are ready, a shareholder meeting could take place in October or November. Surprise, surprise. Now it appears that Taro will not meet these dates either. Taro’s attorney told the judge, “We’re working on it.”
She then went on to take a shot at Taro. “I cannot understand how it is possible to undertake a merger without financial reports. That is a scandal in itself, and contravenes the Companies Law.”
Looks like we have a judge with common sense.
Go Templeton Go!
Please see our Disclaimer HERE.
Disclosure: Author’s fund has no position of any stocks mentioned as of 9/19/07.
Like what you see? Sign up to receive daily updates from IsraelNewsletter here
Aaron Katsman is the lead portfolio manager for the Israel Growth Portfolio and Managing Director of America Israel Investment Associates, LLC. For more information, go to www.israelnewsletter.com or call 1-888-327-6179, or email aaron@profile-financial.com.
